| Similar Articles |
|---|
 |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works.   |
Scientific American
January 17, 2007
Charles Q. Choi |
A Stroke for Stem Cells The brain becomes a target in stem cell clinical trials. |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage. |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
The Motley Fool
May 26, 2009
Brian Orelli |
A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now. |
The Motley Fool
May 15, 2007
Mike Havrilla |
Secret Cytori Cytori may be a lesser-known player in the stem-cell therapy field, but it's a stock to watch in the coming year. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
November 28, 2007
Brian Orelli |
Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
January 4, 2005
W.D. Crotty |
A StemCell First News of an FDA application sends StemCells' stock soaring. |
The Motley Fool
July 23, 2007
Brian Lawler |
Acquisitive Ways Paying Off for Genzyme A recently acquired drug yields positive study results. Genzyme investors, take note. |
Scientific American
March 2007
Alison Snyder |
Sight for Sore Eyes Having generated a cell source and overcome the safety concerns associated with transplanting stem cells, researchers still face possibly their biggest challenge: showing that the transplanted photoreceptors wire up to other neurons that eventually connect to the optic nerves. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
The Motley Fool
October 12, 2010
Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
The Motley Fool
November 14, 2008
Brian Orelli |
Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells. |
Inc.
February 2005
Patrick J. Sauer |
The State of Stem Cell Research Californians are hoping that stem cell research will do for them what the invention of the car did for Michigan. |
Bio-IT World
April 2006 |
Virtual Stem Cell Laboratory Goes Live Children's Hospital in Boston's Virtual Stem Cell Laboratory web site allows online visitors to manipulate and investigate a "living" culture of embryonic stem cells. |
Bio-IT World
August 2005
Maureen McDonough |
U.K. Framework Offers Stem Cells a Future The United Kingdom has managed to cut through the noise surrounding stem cell research, creating a regulatory framework that fosters an environment of international collaboration and excellent R&D programs. And they try to do it all in an ethical way. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Fast Company
December 2009
Elizabeth Svoboda |
Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas. |
Pharmaceutical Executive
March 1, 2007
Sarah Houlton |
Global Report: Ready ... Set ... The European Parliament has launched a formal process for assessing therapies developed through stem-cell research. Ethical issues that have wrangled US regulators, though, still need attention. |
AskMen.com
Dave Golokhov |
Erectile Dysfunction Cure For the first time, stem cells have been used to cure ED in rats with Peyronie's disease, which is a connective tissue disorder in the penis affecting between 3-9% of men. |
BusinessWeek
January 10, 2005
Bruce Einhorn |
Asia Is Stem Cell Central Singapore isn't the only country in the region trying to profit from the U.S. restrictions. Australia, China, India, Japan, and South Korea all see stem cell research as a way to get ahead in biotech. |
Chemistry World
September 24, 2012
Andrew Turley |
Pineapple gel approved for burns NexoBrid gel from privately owned biotech MediWound, contains proteolytic enzymes from the stem of the pineapple plant. |
Pharmaceutical Executive
April 10, 2014
Ben Comer |
Sickle Cell Disease In Three Acts Is there a happy ending in store for sickle cell patients? |
Reactive Reports
Issue 64
David Bradley |
Stem to Sperm New research shows that stem cells from human bone marrow can be converted into early-stage sperm. The discovery could lead to novel fertility treatments in the long-term. |
The Motley Fool
June 21, 2005
Brian Gorman |
Stem Cell Chatter Despite the promise suggested by early studies, embryonic stem cell research remains highly speculative. More concrete results, not the amount of cash being poured into research, are the best basis for investing decisions. |
Scientific American
December 2008
Tim Hornyak |
Turning Back the Cellular Clock: A Farewell to Embryonic Stem Cells? Shinya Yamanaka discovered how to revert adult cells to an embryonic state. These induced pluripotent stem cells might soon supplant their embryonic cousins in therapeutic promise |
The Motley Fool
August 10, 2011
Brandon Glenn |
Athersys More Threatened Than Most by Falling Share Price Recent market movements have been brutal for small biotech Athersys. |
The Motley Fool
May 2, 2011
Brian Orelli |
StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
Chemistry World
August 15, 2007
John Bonner |
Chemists Claim Biological Alchemy South Korean chemists say they have turned muscle cells from the sole of a human foot into something akin to stem cells, using a simple molecule called neurodazine. |
Reason
July 2005
Ronald Bailey |
Censored Science Speaking out on stem cells: The Washington Post noted that even President Bush's handpicked NIH director, Elias Zerhouni, may not be on board with administration's stem cell policy. |
Chemistry World
April 2, 2009
Michael Gross |
Light-guided hydrogels direct cell growth Researchers in the US have developed a gel-like material whose structural and chemical properties can change in response to laser light |
HHMI Bulletin
May 2010
Sarah C.P. Williams |
Lab-Grown Liver New cell culture system solves problem of growing liver cells. |
BusinessWeek
February 12, 2007
Bruce Einhorn |
Stem-Cell Refugees Americans are flocking to China for therapy. |
Scientific American
September 19, 2005
Charles Q. Choi |
Chatting Up Cells Stem cells can transform into whatever cell the body tells them to. Unfortunately, scientists have yet to master that particular gift of gab. But investigators may soon crack the language with tiny "chat rooms" for stem cells. |
The Motley Fool
August 24, 2007
Brian Orelli |
Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it. |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
Reason
October 2001
Ronald Bailey |
Blastocyst Brouhaha Which human cells count as people? |
Chemistry World
April 2010 |
Column: The crucible We are getting better at manipulating cells to grow into the tissues we need. Chemical factors are key, says Philip Ball |
The Motley Fool
May 3, 2005
Charly Travers |
Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not. |
Bio-IT World
July 15, 2003
Kevin Davies |
Stem Cell Suicide The International Society for Stem Cell Research must engage in a political discourse to salvage the hope of embryonic stem cell research. |
Chemistry World
February 4, 2011
Harriet Brewerton |
Transplant tracking Magnetic nanoparticles could be used to track neural stem cells after a transplant in order to monitor how the cells heal spinal injuries, say UK scientists. |
